apparently, without any amendment of the current registration, after roth capital gets done raising $16 million via ipci issuing more shares they can continue selling shares without any specified limit...
" However, in the event our public float subsequently equals or exceeds $75,000,000, we may sell additional amounts under the equity distribution agreement and the Registration Statement of which this Prospectus Supplement and the Prospectus, the 2013 Supplement and the 2014 Supplement are a part, as the limitations on sales under General Instruction I.B.5 of Form F-3 would not then apply."
now, now, one of those holes would be ipci itself
they just filed with the SEC confirming that, depending on the value of the float, they can sell even more shares -- which strongly suggests they have been selling and would like to sell even more via Roth
not even sure where the base is for this latest flagpole
they are going up so fast
one things seems sure -- with all the continuing high volume, elite has established a new plateau
promises to be a very interesting March
dagg, the way i read your statement it sounded like you were describing adam's conclusion as irrefutable. sorry about that. i should have given more weight to the "except" that preceded it
about that placebo snafu -- yes, it is reason for pause but isn't there somewhat of a placebo group represented by everybody out there who has had this cancer and only received SOC treatment? yes, matching is best but it isn't like their is a pocket of patients somewhere that have been living eight, ten, and more years. all of the brain cancer patients have been dying on much the same curve. so, i don't want to be overly dismissive of it but, in the case of brain cancer, i don't think that a unique placebo group is that critical. i mean, really, is there any population or segment of brain cancer patients that have experienced such lengthy freedom from recurrence as Northwest reported from the early trials? so, unless, Northwest was very good at screening candidates, i don't see how the results would have been much different with or without an ironclad placebo group.
as to the koolaid kids on this board -- irritating to the max not because they have necessarily reached a premature or incorrect conclusion but because they find it necessary to post over and over and over when no chickens have yet hatched...
still has catching up to do
partner announcement that gives clear path to completing abuse resistant studies would get it there
company has 72 hours to release the information whether that is weekday, weekend, or middle of the night is up to them
don't know if the company is required to make a public announcement first (or how 'public' is defined), or if they can use that window to get reaction from compassionate use leaning entities like Germany and the U.K.
i'm saying that because if the trials are to continue these other parties may decide during the window that the data looks good enough for them to move forward getting their jurisdictions to approve compassionate use, and this could be rolled into the announcement
it is very, very, unlikely that the trials will be stopped for safety because the vaccine has never caused any adverse reaction and they would not have waited this long to stop if safety had suddenly become an issue
"I own some shares and have read some of Fuerstein's criticism and can't find much fault in his logic.- except that he comes to his own irrefutable conclusion that NWBO's trial will fail like IMUC."
if you believe that adam's conclusion is irrefutable and that Northwest's trials will absolutely fail, how could possibly be so stupid as to own shares here?
but, assuming you hold the shares simply as an alternative to a lottery ticket, how about just admitting that you are a risk conflicted person who wants the giant-sized payoff that can come with stepping out but wants a guarantee, wants proof, before committing?
see, when the proof you seek is there Northwest will be on every institutions radar screen and you will need a fast rocket to catch it
you need to ask yourself how you are going to feel if adam, your guru, is wrong and Northwest soars, and then decide whether that feeling is better or worse than adam being proven right
btw - we think a continuation of the trials would be great, and we do not believe those involved in compassionate use have been anywhere close to koolaid
when you consider all the shares held by Cognate, Toucan, institutions, and Linda, that short position is actually a much, much, larger percentage of what is available for trading
we have a lot of respect for shorts, but this is looking more and more like one of their misses, and they may become a booster rocket to the launch that will occur on good news from these levels
take a look at the one-day chart. see it? seems to have a few birds on its back.
question is, will the buffalo be raising his head, or dipping down for grass, at the close?
read the 'headlines' for elite on yahoo for february 18th -- they are what chased this stock out of the .30's
sounds like your assumption is that oxecta is better than elite's two-bead approach. maybe you could explain why. sure doesn't look like the market agrees.
in the meantime, know this -- addicts will put up with some nasal passage irritation to get high, to your drug is only a deterrent to the less determined
but elite has using a pharmacological approach which means your addict can snort away all day every day and just will not be able to get high
they say there are no stupid questions, but there sure are lazy ones, and yours sure was one...
that approval was u.n.b.e.l.i.e.v.a.b.l.e but it still can be stopped -- my apology for referring to stopping the launch as a final rejection -- and the forces against it are coming together. this is on the newswires today...
"A coalition of addiction experts, physicians and others is urging U.S. health officials to reverse course and block the launch of a powerful painkiller called Zohydro, expected to hit the market next month.
The opioid drug, manufactured by Zogenix Inc, contains a potent amount of an active ingredient that could be lethal to new patients and children and is not safer than other current pain drugs, the groups told the Food and Drug Administration.
"Someone unaccustomed to taking opioids could suffer a fatal overdose from just two capsules. A single capsule could be fatal if swallowed by a child," they wrote in a petition to FDA Commissioner Margaret Hamburg, dated Wednesday.
In December, attorneys general from 28 states also urged the FDA to reconsider its approval of the drug."
this isn't about a buyout, it's about finding a partner with deep pockets to fund the expensive abuse resistant studies -- and to move all of the opioid candidates through as quickly as possible
the new preferred A would allow a partner to assume a near 50% interest assuming 1.3 billion shares outstanding after all conversions
actually, actavis or whomever is going to be elite's partner, may have been buying shares on the open market these past few days just to get up to the 50% mark and be an equal partner going forward, or it could be others in the know that see a partnership coming together
if a partner does not emerge on favorable terms pretty soon, hakim is likely to go with a substantial secondary so that he can get at least one abuse resistant study done. not his preferred route, and not one that we expect given all his contacts, but a possibility. an acceptable course of action, but the studies would then have to be staggered and take longer
those first two statements are fact, the last one is my opinion
why? because hakim has a long history with Actavis, not the least of which it is where he got the drugs he brought with him from mikah, and Actavis has a short history of wanting to get into the oxy market
okay, some drop off has occurred because some doctors were actually running oxy mills, and that is getting cracked (no pun) down on
but more and more law abiding doctors have become reluctant to prescribe what they know to be highly addictive
elite is on the verge of correcting that problem with a true abuse resistant product which will not only cause sales to rebound but even increase because oxy is the best pharmaceutical for pain out there
having said that, we know you missed out on buying ELTP back in november when it was still at .12 and that you would love a second chance, but it is fruitful to try to talk this juggernaut back down. sure it's got quite a ways to go and we won't be selling anything, but you will always be regretting not getting in at .12 even if you did buy in now. so i'm going to suggest that you switch over to our other favorite, NWBO, where you might just get to experience the rocket ride that so many of us have already enjoyed on ELTP
just don't take too long to make up your mind...
well, i've been criticized for being a negative nellie on this board while being a pumper on the ELTP board but i have to say the differences between the two are pretty dramatic. i know that irritates and infuriates those who are invested here, and they want to get into the weeds and argue about it and prove that they are right -- even though the market says they are wrong
see, you and i both know that IPCI is down from where you bought 11/26 while ELTP has gone from .12 to .85
now, again, i've been criticized for picking ELTP over IPCI and for pointing out problems with IPCI but it is important for you going forward to be careful to who you listen to. there are a lot of truly mindless, low information, pompom pumpers on this board, and you would be best to let them stew in their own anger and frustration
as for ELTP, you have already missed out on what would have been an enormous percentage run for you, and you would always be kicking yourself for not getting on board earlier. however, you may reach the same point if you were to clear out of IPCI now, with a very small loss, and put all those chips on NWBO, and it has an advantage over ELTP in that it has active options in case you are the gambling sort
doesn't even seem real, does it
hakim knows a lot of people. since he started making serious contacts with potential partners after the bio-equivalency results, it looks like the word is spreading fast of the bio-equivalency results
oxy is far and away the best pain pharmaceutical out there, but doctors are reluctant to prescribe due to the potential for abuse as it is THE most sought after prescription drug by addicts
elite is on the brink of removing that concern
a doubling would mean a roughly $16 billion market